SND 005
Alternative Names: Rigvir; SND-005Latest Information Update: 07 Jun 2022
At a glance
- Originator Rigvir Group
- Developer Jiangsu Sinorda Biomedicine Co., Ltd; Rigvir Group
- Class Antineoplastics; Immunotherapies; Oncolytic viruses
- Mechanism of Action Cell death stimulants; Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered Malignant melanoma
- Preclinical Solid tumours
Most Recent Events
- 17 May 2022 Adverse events data from a clinical trial in Malignant melanoma released by Jiangsu Sinorda Biomedicine
- 11 May 2022 Preclinical trials in Solid tumours in China (Parenteral) (Jiangsu Sinorda Biomedicine pipeline, May 2022)
- 09 May 2020 SND 005 licensed to Jiangsu Sinorda Biomedicine in China